#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-12	Associations	_
1-2	13-20	between	_
1-3	21-29	drinking	_
1-4	30-33	and	_
1-5	34-42	cortical	_
1-6	43-52	thickness	_
1-7	53-55	in	_
1-8	56-63	younger	_
1-9	64-69	adult	_
1-10	70-78	drinkers	_
1-11	79-80	:	_
1-12	81-89	Findings	_
1-13	90-94	from	_
1-14	95-98	the	_
1-15	99-104	Human	_
1-16	105-115	Connectome	_
1-17	116-123	Project	_
1-18	124-134	Background	_
1-19	135-136	.	_

2-1	137-145	Previous	_
2-2	146-158	neuroimaging	_
2-3	159-166	studies	_
2-4	167-176	examining	_
2-5	177-186	relations	_
2-6	187-194	between	_
2-7	195-202	alcohol	_
2-8	203-209	misuse	_
2-9	210-213	and	_
2-10	214-222	cortical	_
2-11	223-232	thickness	_
2-12	233-237	have	_
2-13	238-246	revealed	_
2-14	247-251	that	_
2-15	252-261	increased	_
2-16	262-270	drinking	_
2-17	271-279	quantity	_
2-18	280-283	and	_
2-19	284-299	alcohol-related	_
2-20	300-308	problems	_
2-21	309-312	are	_
2-22	313-323	associated	_
2-23	324-328	with	_
2-24	329-336	thinner	_
2-25	337-343	cortex	_
2-26	344-345	.	_

3-1	346-354	Although	_
3-2	355-366	conflicting	_
3-3	367-375	regional	_
3-4	376-383	effects	_
3-5	384-387	are	_
3-6	388-393	often	_
3-7	394-402	observed	_
3-8	403-404	,	_
3-9	405-417	associations	_
3-10	418-421	are	_
3-11	422-431	generally	_
3-12	432-441	localized	_
3-13	442-444	to	_
3-14	445-452	frontal	_
3-15	453-460	regions	_
3-16	461-462	(	_
3-17	463-467	e.g.	_
3-18	468-469	,	_
3-19	470-482	dorsolateral	_
3-20	483-493	prefrontal	_
3-21	494-500	cortex	_
3-22	501-502	(	_
3-23	503-508	DLPFC	_
3-24	509-510	)	_
3-25	511-512	,	_
3-26	513-521	inferior	_
3-27	522-529	frontal	_
3-28	530-535	gyrus	_
3-29	536-537	(	_
3-30	538-541	IFG	_
3-31	542-543	)	_
3-32	544-545	,	_
3-33	546-549	and	_
3-34	550-558	anterior	_
3-35	559-568	cingulate	_
3-36	569-575	cortex	_
3-37	576-577	)	_
3-38	578-579	.	_

4-1	580-592	Inconsistent	_
4-2	593-601	findings	_
4-3	602-605	may	_
4-4	606-608	be	_
4-5	609-619	attributed	_
4-6	620-622	to	_
4-7	623-637	methodological	_
4-8	638-649	differences	_
4-9	650-651	,	_
4-10	652-658	modest	_
4-11	659-665	sample	_
4-12	666-671	sizes	_
4-13	672-673	,	_
4-14	674-677	and	_
4-15	678-685	limited	_
4-16	686-699	consideration	_
4-17	700-702	of	_
4-18	703-706	sex	_
4-19	707-718	differences	_
4-20	719-720	.	_

5-1	721-727	Method	_
5-2	728-729	.	_

6-1	730-734	This	_
6-2	735-740	study	_
6-3	741-749	examined	_
6-4	750-765	neuroanatomical	_
6-5	766-776	correlates	_
6-6	777-779	of	_
6-7	780-788	drinking	_
6-8	789-797	quantity	_
6-9	798-801	and	_
6-10	802-807	heavy	_
6-11	808-816	episodic	_
6-12	817-825	drinking	_
6-13	826-828	in	_
6-14	829-830	a	_
6-15	831-836	large	_
6-16	837-843	sample	_
6-17	844-846	of	_
6-18	847-854	younger	_
6-19	855-861	adults	_
6-20	862-863	(	_
6-21	864-869	N=706	_
6-22	870-871	;	_
6-23	872-873	M	_
6-24	874-877	age	_
6-25	878-879	=	_
6-26	880-884	28.8	_
6-27	885-886	;	_
6-28	887-889	51	_
6-29	890-891	%	_
6-30	892-898	female	_
6-31	899-900	)	_
6-32	901-906	using	_
6-33	907-915	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-34	916-925	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-35	926-933	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-36	934-938	data	_
6-37	939-943	from	_
6-38	944-947	the	_
6-39	948-953	Human	_
6-40	954-964	Connectome	_
6-41	965-972	Project	_
6-42	973-974	.	_

7-1	975-986	Exploratory	_
7-2	987-995	analyses	_
7-3	996-1004	examined	_
7-4	1005-1020	neuroanatomical	_
7-5	1021-1031	correlates	_
7-6	1032-1034	of	_
7-7	1035-1044	executive	_
7-8	1045-1053	function	_
7-9	1054-1055	(	_
7-10	1056-1063	flanker	_
7-11	1064-1068	task	_
7-12	1069-1070	)	_
7-13	1071-1074	and	_
7-14	1075-1082	working	_
7-15	1083-1089	memory	_
7-16	1090-1091	(	_
7-17	1092-1096	list	_
7-18	1097-1104	sorting	_
7-19	1105-1106	)	_
7-20	1107-1108	.	_

8-1	1109-1116	Results	_
8-2	1117-1118	.	_

9-1	1119-1131	Hierarchical	_
9-2	1132-1138	linear	_
9-3	1139-1149	regression	_
9-4	1150-1156	models	_
9-5	1157-1158	(	_
9-6	1159-1170	controlling	_
9-7	1171-1174	for	_
9-8	1175-1178	age	_
9-9	1179-1180	,	_
9-10	1181-1184	sex	_
9-11	1185-1186	,	_
9-12	1187-1196	education	_
9-13	1197-1198	,	_
9-14	1199-1205	income	_
9-15	1206-1207	,	_
9-16	1208-1215	smoking	_
9-17	1216-1217	,	_
9-18	1218-1222	drug	_
9-19	1223-1226	use	_
9-20	1227-1228	,	_
9-21	1229-1233	twin	_
9-22	1234-1240	status	_
9-23	1241-1242	,	_
9-24	1243-1246	and	_
9-25	1247-1259	intracranial	_
9-26	1260-1266	volume	_
9-27	1267-1268	)	_
9-28	1269-1277	revealed	_
9-29	1278-1289	significant	_
9-30	1290-1297	inverse	_
9-31	1298-1310	associations	_
9-32	1311-1318	between	_
9-33	1319-1325	drinks	_
9-34	1326-1328	in	_
9-35	1329-1333	past	_
9-36	1334-1338	week	_
9-37	1339-1342	and	_
9-38	1343-1352	frequency	_
9-39	1353-1355	of	_
9-40	1356-1361	heavy	_
9-41	1362-1370	drinking	_
9-42	1371-1374	and	_
9-43	1375-1383	cortical	_
9-44	1384-1393	thickness	_
9-45	1394-1396	in	_
9-46	1397-1398	a	_
9-47	1399-1407	majority	_
9-48	1408-1410	of	_
9-49	1411-1418	regions	_
9-50	1419-1427	examined	_
9-51	1428-1429	.	_

10-1	1430-1433	The	_
10-2	1434-1441	largest	_
10-3	1442-1448	effect	_
10-4	1449-1454	sizes	_
10-5	1455-1459	were	_
10-6	1460-1465	found	_
10-7	1466-1469	for	_
10-8	1470-1477	frontal	_
10-9	1478-1485	regions	_
10-10	1486-1487	(	_
10-11	1488-1493	DLPFC	_
10-12	1494-1495	,	_
10-13	1496-1499	IFG	_
10-14	1500-1501	,	_
10-15	1502-1505	and	_
10-16	1506-1509	the	_
10-17	1510-1520	precentral	_
10-18	1521-1526	gyrus	_
10-19	1527-1528	)	_
10-20	1529-1530	.	_

11-1	1531-1540	Follow-up	_
11-2	1541-1551	regression	_
11-3	1552-1558	models	_
11-4	1559-1567	revealed	_
11-5	1568-1572	that	_
11-6	1573-1576	the	_
11-7	1577-1581	left	_
11-8	1582-1587	DLPFC	_
11-9	1588-1591	was	_
11-10	1592-1600	uniquely	_
11-11	1601-1611	associated	_
11-12	1612-1616	with	_
11-13	1617-1621	both	_
11-14	1622-1630	drinking	_
11-15	1631-1640	variables	_
11-16	1641-1642	.	_

12-1	1643-1646	Sex	_
12-2	1647-1658	differences	_
12-3	1659-1663	were	_
12-4	1664-1668	also	_
12-5	1669-1677	observed	_
12-6	1678-1679	,	_
12-7	1680-1684	with	_
12-8	1685-1696	significant	_
12-9	1697-1704	effects	_
12-10	1705-1712	largely	_
12-11	1713-1721	specific	_
12-12	1722-1724	to	_
12-13	1725-1728	men	_
12-14	1729-1730	.	_

13-1	1731-1742	Conclusions	_
13-2	1743-1744	.	_

14-1	1745-1749	This	_
14-2	1750-1755	study	_
14-3	1756-1760	adds	_
14-4	1761-1763	to	_
14-5	1764-1767	the	_
14-6	1768-1781	understanding	_
14-7	1782-1784	of	_
14-8	1785-1790	brain	_
14-9	1791-1801	correlates	_
14-10	1802-1804	of	_
14-11	1805-1812	alcohol	_
14-12	1813-1816	use	_
14-13	1817-1819	in	_
14-14	1820-1821	a	_
14-15	1822-1827	large	_
14-16	1828-1829	,	_
14-17	1830-1845	gender-balanced	_
14-18	1846-1852	sample	_
14-19	1853-1855	of	_
14-20	1856-1863	younger	_
14-21	1864-1870	adults	_
14-22	1871-1872	.	_

15-1	1873-1881	Although	_
15-2	1882-1885	the	_
15-3	1886-1901	cross-sectional	_
15-4	1902-1913	methodology	_
15-5	1914-1923	precludes	_
15-6	1924-1930	causal	_
15-7	1931-1941	inferences	_
15-8	1942-1943	,	_
15-9	1944-1949	these	_
15-10	1950-1958	findings	_
15-11	1959-1966	provide	_
15-12	1967-1968	a	_
15-13	1969-1979	foundation	_
15-14	1980-1983	for	_
15-15	1984-1992	rigorous	_
15-16	1993-2003	hypothesis	_
15-17	2004-2011	testing	_
15-18	2012-2014	in	_
15-19	2015-2021	future	_
15-20	2022-2034	longitudinal	_
15-21	2035-2049	investigations	_
15-22	2050-2051	.	_

16-1	2052-2061	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-2	2062-2065	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-3	2066-2073	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-4	2074-2086	Participants	_
16-5	2087-2097	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-6	2098-2101	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
16-7	2102-2107	brain	_
16-8	2108-2113	scans	_
16-9	2114-2118	were	_
16-10	2119-2124	drawn	_
16-11	2125-2129	from	_
16-12	2130-2133	the	_
16-13	2134-2138	1200	_
16-14	2139-2147	Subjects	_
16-15	2148-2151	HCP	_
16-16	2152-2159	dataset	_
16-17	2160-2161	(	_
16-18	2162-2170	released	_
16-19	2171-2176	March	_
16-20	2177-2178	1	_
16-21	2179-2180	,	_
16-22	2181-2185	2017	_
16-23	2186-2187	;	_
16-24	2188-2197	available	_
16-25	2198-2200	at	_
16-26	2201-2205	http	_
16-27	2206-2207	:	_
16-28	2208-2234	//www.humanconnectome.org/	_
16-29	2235-2236	)	_
16-30	2237-2238	.	_

17-1	2239-2242	The	_
17-2	2243-2250	primary	_
17-3	2251-2254	HCP	_
17-4	2255-2266	participant	_
17-5	2267-2271	pool	_
17-6	2272-2281	consisted	_
17-7	2282-2284	of	_
17-8	2285-2294	community	_
17-9	2295-2301	adults	_
17-10	2302-2309	between	_
17-11	2310-2313	the	_
17-12	2314-2318	ages	_
17-13	2319-2321	of	_
17-14	2322-2327	22–37	_
17-15	2328-2329	.	_

18-1	2330-2342	Participants	_
18-2	2343-2347	were	_
18-3	2348-2356	excluded	_
18-4	2357-2361	from	_
18-5	2362-2365	the	_
18-6	2366-2369	HCP	_
18-7	2370-2375	study	_
18-8	2376-2378	if	_
18-9	2379-2383	they	_
18-10	2384-2387	had	_
18-11	2388-2389	a	_
18-12	2390-2397	history	_
18-13	2398-2400	of	_
18-14	2401-2419	neurodevelopmental	_
18-15	2420-2421	,	_
18-16	2422-2438	neuropsychiatric	_
18-17	2439-2440	,	_
18-18	2441-2443	or	_
18-19	2444-2456	neurological	_
18-20	2457-2466	disorders	_
18-21	2467-2468	,	_
18-22	2469-2471	as	_
18-23	2472-2476	well	_
18-24	2477-2479	as	_
18-25	2480-2491	significant	_
18-26	2492-2499	medical	_
18-27	2500-2510	conditions	_
18-28	2511-2515	such	_
18-29	2516-2518	as	_
18-30	2519-2527	diabetes	_
18-31	2528-2530	or	_
18-32	2531-2535	high	_
18-33	2536-2541	blood	_
18-34	2542-2550	pressure	_
18-35	2551-2552	.	_

19-1	2553-2556	The	_
19-2	2557-2560	use	_
19-3	2561-2563	of	_
19-4	2564-2569	drugs	_
19-5	2570-2572	or	_
19-6	2573-2580	tobacco	_
19-7	2581-2585	were	_
19-8	2586-2589	not	_
19-9	2590-2602	exclusionary	_
19-10	2603-2606	and	_
19-11	2607-2612	these	_
19-12	2613-2622	variables	_
19-13	2623-2627	were	_
19-14	2628-2636	included	_
19-15	2637-2639	as	_
19-16	2640-2650	covariates	_
19-17	2651-2653	in	_
19-18	2654-2657	all	_
19-19	2658-2666	analyses	_
19-20	2667-2668	(	_
19-21	2669-2672	see	_
19-22	2673-2678	below	_
19-23	2679-2680	)	_
19-24	2681-2682	.	_

20-1	2683-2686	The	_
20-2	2687-2694	current	_
20-3	2695-2700	study	_
20-4	2701-2707	sample	_
20-5	2708-2717	consisted	_
20-6	2718-2720	of	_
20-7	2721-2724	HCP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-8	2725-2737	participants	_
20-9	2738-2741	who	_
20-10	2742-2750	reported	_
20-11	2751-2760	consuming	_
20-12	2761-2763	at	_
20-13	2764-2769	least	_
20-14	2770-2773	one	_
20-15	2774-2783	alcoholic	_
20-16	2784-2789	drink	_
20-17	2790-2792	in	_
20-18	2793-2796	the	_
20-19	2797-2806	past-week	_
20-20	2807-2820	retrospective	_
20-21	2821-2828	alcohol	_
20-22	2829-2839	assessment	_
20-23	2840-2841	(	_
20-24	2842-2849	details	_
20-25	2850-2855	below	_
20-26	2856-2857	)	_
20-27	2858-2859	,	_
20-28	2860-2869	resulting	_
20-29	2870-2872	in	_
20-30	2873-2874	a	_
20-31	2875-2881	sample	_
20-32	2882-2884	of	_
20-33	2885-2888	711	_
20-34	2889-2901	participants	_
20-35	2902-2903	.	_

21-1	2904-2906	An	_
21-2	2907-2917	additional	_
21-3	2918-2919	5	_
21-4	2920-2932	participants	_
21-5	2933-2937	were	_
21-6	2938-2946	excluded	_
21-7	2947-2950	due	_
21-8	2951-2953	to	_
21-9	2954-2964	incomplete	_
21-10	2965-2969	data	_
21-11	2970-2971	(	_
21-12	2972-2973	3	_
21-13	2974-2977	did	_
21-14	2978-2981	not	_
21-15	2982-2990	complete	_
21-16	2991-2994	the	_
21-17	2995-3003	drinking	_
21-18	3004-3015	assessments	_
21-19	3016-3017	,	_
21-20	3018-3021	and	_
21-21	3022-3023	2	_
21-22	3024-3027	did	_
21-23	3028-3031	not	_
21-24	3032-3039	provide	_
21-25	3040-3044	full	_
21-26	3045-3056	demographic	_
21-27	3057-3068	information	_
21-28	3069-3070	)	_
21-29	3071-3072	.	_

22-1	3073-3076	The	_
22-2	3077-3082	final	_
22-3	3083-3089	sample	_
22-4	3090-3099	consisted	_
22-5	3100-3102	of	_
22-6	3103-3106	706	_
22-7	3107-3119	participants	_
22-8	3120-3121	.	_

23-1	3122-3133	Assessments	_
23-2	3134-3140	Access	_
23-3	3141-3143	to	_
23-4	3144-3154	restricted	_
23-5	3155-3166	participant	_
23-6	3167-3178	demographic	_
23-7	3179-3182	and	_
23-8	3183-3191	clinical	_
23-9	3192-3196	data	_
23-10	3197-3200	was	_
23-11	3201-3208	granted	_
23-12	3209-3212	via	_
23-13	3213-3220	written	_
23-14	3221-3234	authorization	_
23-15	3235-3239	from	_
23-16	3240-3243	the	_
23-17	3244-3247	HCP	_
23-18	3248-3258	Connectome	_
23-19	3259-3271	Coordination	_
23-20	3272-3280	Facility	_
23-21	3281-3282	.	_

24-1	3283-3295	Participants	_
24-2	3296-3305	completed	_
24-3	3306-3309	the	_
24-4	3310-3325	Semi-Structured	_
24-5	3326-3336	Assessment	_
24-6	3337-3340	for	_
24-7	3341-3344	the	_
24-8	3345-3353	Genetics	_
24-9	3354-3356	of	_
24-10	3357-3367	Alcoholism	_
24-11	3368-3369	(	_
24-12	3370-3375	SSAGA	_
24-13	3376-3377	,	_
24-14	3378-3379	)	_
24-15	3380-3381	.	_

25-1	3382-3385	The	_
25-2	3386-3391	SSAGA	_
25-3	3392-3400	assesses	_
25-4	3401-3409	physical	_
25-5	3410-3411	,	_
25-6	3412-3425	psychological	_
25-7	3426-3427	,	_
25-8	3428-3431	and	_
25-9	3432-3438	social	_
25-10	3439-3447	symptoms	_
25-11	3448-3450	of	_
25-12	3451-3458	alcohol	_
25-13	3459-3464	abuse	_
25-14	3465-3468	and	_
25-15	3469-3479	dependence	_
25-16	3480-3482	as	_
25-17	3483-3487	well	_
25-18	3488-3490	as	_
25-19	3491-3496	other	_
25-20	3497-3508	psychiatric	_
25-21	3509-3518	disorders	_
25-22	3519-3524	using	_
25-23	3525-3534	DSM-III-R	_
25-24	3535-3538	and	_
25-25	3539-3545	DSM-IV	_
25-26	3546-3554	criteria	_
25-27	3555-3556	.	_

26-1	3557-3560	The	_
26-2	3561-3566	SSAGA	_
26-3	3567-3571	also	_
26-4	3572-3578	covers	_
26-5	3579-3586	general	_
26-6	3587-3598	demographic	_
26-7	3599-3610	information	_
26-8	3611-3612	,	_
26-9	3613-3620	medical	_
26-10	3621-3628	history	_
26-11	3629-3630	,	_
26-12	3631-3642	information	_
26-13	3643-3648	about	_
26-14	3649-3656	tobacco	_
26-15	3657-3660	and	_
26-16	3661-3665	drug	_
26-17	3666-3669	use	_
26-18	3670-3671	,	_
26-19	3672-3675	and	_
26-20	3676-3681	other	_
26-21	3682-3688	mental	_
26-22	3689-3695	health	_
26-23	3696-3705	variables	_
26-24	3706-3707	.	_

27-1	3708-3720	Participants	_
27-2	3721-3725	also	_
27-3	3726-3735	completed	_
27-4	3736-3737	a	_
27-5	3738-3747	seven-day	_
27-6	3748-3761	retrospective	_
27-7	3762-3768	report	_
27-8	3769-3771	of	_
27-9	3772-3779	alcohol	_
27-10	3780-3783	and	_
27-11	3784-3791	tobacco	_
27-12	3792-3795	use	_
27-13	3796-3797	.	_

28-1	3798-3810	Participants	_
28-2	3811-3819	provided	_
28-3	3820-3821	a	_
28-4	3822-3834	commercially	_
28-5	3835-3844	available	_
28-6	3845-3850	urine	_
28-7	3851-3855	drug	_
28-8	3856-3862	screen	_
28-9	3863-3866	for	_
28-10	3867-3878	biochemical	_
28-11	3879-3886	testing	_
28-12	3887-3889	of	_
28-13	3890-3896	recent	_
28-14	3897-3901	drug	_
28-15	3902-3905	use	_
28-16	3906-3907	.	_

29-1	3908-3911	Two	_
29-2	3912-3926	neurocognitive	_
29-3	3927-3935	measures	_
29-4	3936-3940	from	_
29-5	3941-3944	the	_
29-6	3945-3948	HCP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-7	3949-3959	behavioral	_
29-8	3960-3970	assessment	_
29-9	3971-3978	battery	_
29-10	3979-3983	were	_
29-11	3984-3992	assessed	_
29-12	3993-3997	here	_
29-13	3998-3999	.	_

30-1	4000-4005	These	_
30-2	4006-4014	measures	_
30-3	4015-4019	were	_
30-4	4020-4025	drawn	_
30-5	4026-4030	from	_
30-6	4031-4034	the	_
30-7	4035-4038	NIH	_
30-8	4039-4046	Toolbox	_
30-9	4047-4048	(	_
30-10	4049-4053	http	_
30-11	4054-4055	:	_
30-12	4056-4119	//www.healthmeasures.net/exploremeasurement-systems/nih-toolbox	_
30-13	4120-4121	)	_
30-14	4122-4123	,	_
30-15	4124-4133	including	_
30-16	4134-4135	a	_
30-17	4136-4143	measure	_
30-18	4144-4146	of	_
30-19	4147-4156	executive	_
30-20	4157-4176	function/inhibition	_
30-21	4177-4178	(	_
30-22	4179-4186	flanker	_
30-23	4187-4191	task	_
30-24	4192-4193	)	_
30-25	4194-4197	and	_
30-26	4198-4199	a	_
30-27	4200-4207	measure	_
30-28	4208-4210	of	_
30-29	4211-4218	working	_
30-30	4219-4225	memory	_
30-31	4226-4227	(	_
30-32	4228-4232	list	_
30-33	4233-4240	sorting	_
30-34	4241-4242	)	_
30-35	4243-4244	.	_

31-1	4245-4249	Full	_
31-2	4250-4257	details	_
31-3	4258-4260	of	_
31-4	4261-4264	the	_
31-5	4265-4268	HCP	_
31-6	4269-4279	behavioral	_
31-7	4280-4288	measures	_
31-8	4289-4292	are	_
31-9	4293-4301	provided	_
31-10	4302-4311	elsewhere	_
31-11	4312-4313	.	_

32-1	4314-4321	Alcohol	_
32-2	4322-4331	Variables	_
32-3	4332-4335	Two	_
32-4	4336-4343	alcohol	_
32-5	4344-4353	variables	_
32-6	4354-4358	from	_
32-7	4359-4362	the	_
32-8	4363-4366	HCP	_
32-9	4367-4374	dataset	_
32-10	4375-4379	were	_
32-11	4380-4388	examined	_
32-12	4389-4391	in	_
32-13	4392-4395	the	_
32-14	4396-4403	current	_
32-15	4404-4409	study	_
32-16	4410-4411	.	_

33-1	4412-4415	The	_
33-2	4416-4421	first	_
33-3	4422-4423	,	_
33-4	4424-4425	“	_
33-5	4426-4431	Total	_
33-6	4432-4438	drinks	_
33-7	4439-4441	in	_
33-8	4442-4446	past	_
33-9	4447-4448	7	_
33-10	4449-4453	days	_
33-11	4454-4455	”	_
33-12	4456-4457	,	_
33-13	4458-4461	was	_
33-14	4462-4467	taken	_
33-15	4468-4472	from	_
33-16	4473-4476	the	_
33-17	4477-4490	retrospective	_
33-18	4491-4498	alcohol	_
33-19	4499-4502	use	_
33-20	4503-4513	assessment	_
33-21	4514-4515	.	_

34-1	4516-4519	The	_
34-2	4520-4526	second	_
34-3	4527-4528	,	_
34-4	4529-4530	“	_
34-5	4531-4540	Frequency	_
34-6	4541-4543	of	_
34-7	4544-4552	drinking	_
34-8	4553-4555	5+	_
34-9	4556-4562	drinks	_
34-10	4563-4565	in	_
34-11	4566-4570	past	_
34-12	4571-4573	12	_
34-13	4574-4580	months	_
34-14	4581-4582	”	_
34-15	4583-4584	,	_
34-16	4585-4588	was	_
34-17	4589-4594	taken	_
34-18	4595-4599	from	_
34-19	4600-4603	the	_
34-20	4604-4609	SSAGA	_
34-21	4610-4620	assessment	_
34-22	4621-4622	.	_

35-1	4623-4627	This	_
35-2	4628-4636	variable	_
35-3	4637-4640	was	_
35-4	4641-4646	coded	_
35-5	4647-4660	categorically	_
35-6	4661-4663	in	_
35-7	4664-4667	the	_
35-8	4668-4671	HCP	_
35-9	4672-4679	dataset	_
35-10	4680-4681	,	_
35-11	4682-4685	but	_
35-12	4686-4689	the	_
35-13	4690-4696	coding	_
35-14	4697-4700	for	_
35-15	4701-4704	the	_
35-16	4705-4712	highest	_
35-17	4713-4722	frequency	_
35-18	4723-4731	differed	_
35-19	4732-4735	for	_
35-20	4736-4741	males	_
35-21	4742-4745	and	_
35-22	4746-4753	females	_
35-23	4754-4755	(	_
35-24	4756-4760	i.e.	_
35-25	4761-4762	,	_
35-26	4763-4766	the	_
35-27	4767-4774	maximum	_
35-28	4775-4783	response	_
35-29	4784-4786	of	_
35-30	4787-4789	3+	_
35-31	4790-4799	days/week	_
35-32	4800-4803	was	_
35-33	4804-4809	coded	_
35-34	4810-4812	as	_
35-35	4813-4814	1	_
35-36	4815-4818	for	_
35-37	4819-4824	males	_
35-38	4825-4826	,	_
35-39	4827-4830	but	_
35-40	4831-4832	2	_
35-41	4833-4836	for	_
35-42	4837-4844	females	_
35-43	4845-4846	)	_
35-44	4847-4848	.	_

36-1	4849-4852	The	_
36-2	4853-4857	next	_
36-3	4858-4864	lowest	_
36-4	4865-4870	value	_
36-5	4871-4872	(	_
36-6	4873-4876	1–2	_
36-7	4877-4886	days/week	_
36-8	4887-4888	)	_
36-9	4889-4892	was	_
36-10	4893-4898	coded	_
36-11	4899-4901	as	_
36-12	4902-4903	2	_
36-13	4904-4907	for	_
36-14	4908-4912	both	_
36-15	4913-4918	males	_
36-16	4919-4922	and	_
36-17	4923-4930	females	_
36-18	4931-4932	.	_

37-1	4933-4942	Therefore	_
37-2	4943-4944	,	_
37-3	4945-4947	no	_
37-4	4948-4959	distinction	_
37-5	4960-4965	could	_
37-6	4966-4968	be	_
37-7	4969-4973	made	_
37-8	4974-4981	between	_
37-9	4982-4985	1–2	_
37-10	4986-4989	vs.	_
37-11	4990-4992	3+	_
37-12	4993-5002	days/week	_
37-13	5003-5006	for	_
37-14	5007-5014	females	_
37-15	5015-5016	.	_

38-1	5017-5019	To	_
38-2	5020-5031	standardize	_
38-3	5032-5035	the	_
38-4	5036-5043	maximum	_
38-5	5044-5052	response	_
38-6	5053-5054	,	_
38-7	5055-5058	the	_
38-8	5059-5063	data	_
38-9	5064-5068	were	_
38-10	5069-5076	recoded	_
38-11	5077-5079	as	_
38-12	5080-5087	follows	_
38-13	5088-5089	(	_
38-14	5090-5093	and	_
38-15	5094-5108	reverse-scored	_
38-16	5109-5113	such	_
38-17	5114-5118	that	_
38-18	5119-5125	higher	_
38-19	5126-5132	values	_
38-20	5133-5140	reflect	_
38-21	5141-5148	greater	_
38-22	5149-5158	frequency	_
38-23	5159-5160	)	_
38-24	5161-5162	:	_
38-25	5163-5164	1	_
38-26	5165-5166	=	_
38-27	5167-5172	never	_
38-28	5173-5174	;	_
38-29	5175-5179	1–11	_
38-30	5180-5189	days/year	_
38-31	5190-5191	=	_
38-32	5192-5193	2	_
38-33	5194-5195	;	_
38-34	5196-5198	13	_
38-35	5199-5209	days/month	_
38-36	5210-5211	=	_
38-37	5212-5213	3	_
38-38	5214-5215	;	_
38-39	5216-5222	weekly	_
38-40	5223-5225	or	_
38-41	5226-5233	greater	_
38-42	5234-5235	=	_
38-43	5236-5237	4	_
38-44	5238-5239	.	_

39-1	5240-5249	Selection	_
39-2	5250-5252	of	_
39-3	5253-5258	these	_
39-4	5259-5262	two	_
39-5	5263-5270	alcohol	_
39-6	5271-5280	variables	_
39-7	5281-5284	was	_
39-8	5285-5290	based	_
39-9	5291-5293	on	_
39-10	5294-5302	previous	_
39-11	5303-5311	research	_
39-12	5312-5321	examining	_
39-13	5322-5332	continuous	_
39-14	5333-5345	associations	_
39-15	5346-5353	between	_
39-16	5354-5360	recent	_
39-17	5361-5369	drinking	_
39-18	5370-5378	quantity	_
39-19	5379-5382	and	_
39-20	5383-5391	cortical	_
39-21	5392-5401	thickness	_
39-22	5402-5403	(	_
39-23	5404-5408	e.g.	_
39-24	5409-5410	,	_
39-25	5411-5412	)	_
39-26	5413-5416	and	_
39-27	5417-5422	prior	_
39-28	5423-5431	research	_
39-29	5432-5436	that	_
39-30	5437-5444	focused	_
39-31	5445-5457	specifically	_
39-32	5458-5460	on	_
39-33	5461-5471	structural	_
39-34	5472-5477	brain	_
39-35	5478-5488	correlates	_
39-36	5489-5491	of	_
39-37	5492-5497	binge	_
39-38	5498-5506	drinking	_
39-39	5507-5509	as	_
39-40	5510-5511	a	_
39-41	5512-5518	unique	_
39-42	5519-5528	predictor	_
39-43	5529-5531	of	_
39-44	5532-5540	cortical	_
39-45	5541-5550	thickness	_
39-46	5551-5562	differences	_
39-47	5563-5564	(	_
39-48	5565-5569	e.g.	_
39-49	5570-5571	,	_
39-50	5572-5573	)	_
39-51	5574-5575	.	_

40-1	5576-5579	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-2	5580-5584	Data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-3	5585-5596	Acquisition	_
40-4	5597-5600	and	_
40-5	5601-5605	Data	_
40-6	5606-5613	Quality	_
40-7	5614-5621	Control	_
40-8	5622-5637	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
40-9	5638-5649	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-10	5650-5660	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-11	5661-5667	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-12	5668-5672	were	_
40-13	5673-5682	collected	_
40-14	5683-5685	on	_
40-15	5686-5687	a	_
40-16	5688-5690	3T	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
40-17	5691-5698	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
40-18	5699-5704	Skyra	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
40-19	5705-5712	scanner	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
40-20	5713-5714	(	_
40-21	5715-5722	Siemens	_
40-22	5723-5725	AG	_
40-23	5726-5727	,	_
40-24	5728-5736	Erlanger	_
40-25	5737-5738	,	_
40-26	5739-5746	Germany	_
40-27	5747-5748	)	_
40-28	5749-5753	with	_
40-29	5754-5755	a	_
40-30	5756-5766	32-channel	_
40-31	5767-5771	head	_
40-32	5772-5776	coil	_
40-33	5777-5778	(	_
40-34	5779-5782	for	_
40-35	5783-5787	full	_
40-36	5788-5799	acquisition	_
40-37	5800-5808	protocol	_
40-38	5809-5810	,	_
40-39	5811-5814	see	_
40-40	5815-5816	)	_
40-41	5817-5818	.	_

41-1	5819-5826	Briefly	_
41-2	5827-5828	,	_
41-3	5829-5835	images	_
41-4	5836-5840	were	_
41-5	5841-5849	acquired	_
41-6	5850-5854	with	_
41-7	5855-5856	a	_
41-8	5857-5860	0.7	_
41-9	5861-5864	mm3	_
41-10	5865-5874	isotropic	_
41-11	5875-5885	resolution	_
41-12	5886-5887	(	_
41-13	5888-5891	FOV	_
41-14	5892-5893	=	_
41-15	5894-5897	224	_
41-16	5898-5899	×	_
41-17	5900-5903	240	_
41-18	5904-5905	,	_
41-19	5906-5912	matrix	_
41-20	5913-5914	=	_
41-21	5915-5918	320	_
41-22	5919-5920	×	_
41-23	5921-5924	320	_
41-24	5925-5926	,	_
41-25	5927-5930	256	_
41-26	5931-5939	sagittal	_
41-27	5940-5946	slices	_
41-28	5947-5948	;	_
41-29	5949-5951	TR	_
41-30	5952-5953	=	_
41-31	5954-5958	2400	_
41-32	5959-5961	ms	_
41-33	5962-5965	and	_
41-34	5966-5968	TE	_
41-35	5969-5970	=	_
41-36	5971-5975	2.14	_
41-37	5976-5978	ms	_
41-38	5979-5980	)	_
41-39	5981-5982	.	_

42-1	5983-5992	Following	_
42-2	5993-5996	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-3	5997-5998	,	_
42-4	5999-6003	each	_
42-5	6004-6014	structural	_
42-6	6015-6019	scan	_
42-7	6020-6023	was	_
42-8	6024-6032	examined	_
42-9	6033-6035	by	_
42-10	6036-6037	a	_
42-11	6038-6045	trained	_
42-12	6046-6051	rater	_
42-13	6052-6054	to	_
42-14	6055-6061	assess	_
42-15	6062-6065	the	_
42-16	6066-6073	overall	_
42-17	6074-6081	quality	_
42-18	6082-6084	of	_
42-19	6085-6088	the	_
42-20	6089-6093	scan	_
42-21	6094-6095	’	_
42-22	6096-6097	s	_
42-23	6098-6106	contrast	_
42-24	6107-6108	,	_
42-25	6109-6117	blurring	_
42-26	6118-6119	,	_
42-27	6120-6127	ringing	_
42-28	6128-6129	,	_
42-29	6130-6133	and	_
42-30	6134-6139	other	_
42-31	6140-6148	possible	_
42-32	6149-6158	artifacts	_
42-33	6159-6160	.	_

43-1	6161-6165	Only	_
43-2	6166-6169	the	_
43-3	6170-6175	scans	_
43-4	6176-6181	rated	_
43-5	6182-6184	as	_
43-6	6185-6194	excellent	_
43-7	6195-6199	were	_
43-8	6200-6208	released	_
43-9	6209-6211	as	_
43-10	6212-6216	part	_
43-11	6217-6219	of	_
43-12	6220-6223	the	_
43-13	6224-6227	HCP	_
43-14	6228-6235	dataset	_
43-15	6236-6237	.	_

44-1	6238-6241	For	_
44-2	6242-6246	full	_
44-3	6247-6258	explanation	_
44-4	6259-6261	of	_
44-5	6262-6265	HCP	_
44-6	6266-6273	quality	_
44-7	6274-6281	control	_
44-8	6282-6292	procedures	_
44-9	6293-6294	,	_
44-10	6295-6298	see	_
44-11	6299-6300	.	_

45-1	6301-6311	FreeSurfer	_
45-2	6312-6322	Processing	_
45-3	6323-6332	Pipelines	_
45-4	6333-6341	Cortical	_
45-5	6342-6351	thickness	_
45-6	6352-6356	data	_
45-7	6357-6361	were	_
45-8	6362-6371	generated	_
45-9	6372-6377	using	_
45-10	6378-6381	the	_
45-11	6382-6385	HCP	_
45-12	6386-6393	minimal	_
45-13	6394-6407	preprocessing	_
45-14	6408-6416	pipeline	_
45-15	6417-6426	described	_
45-16	6427-6429	in	_
45-17	6430-6431	.	_

46-1	6432-6434	In	_
46-2	6435-6438	the	_
46-3	6439-6444	first	_
46-4	6445-6449	part	_
46-5	6450-6452	of	_
46-6	6453-6456	the	_
46-7	6457-6465	pipeline	_
46-8	6466-6467	,	_
46-9	6468-6481	PreFreeSurfer	_
46-10	6482-6484	is	_
46-11	6485-6489	used	_
46-12	6490-6492	to	_
46-13	6493-6500	produce	_
46-14	6501-6502	a	_
46-15	6503-6508	clear	_
46-16	6509-6519	structural	_
46-17	6520-6526	volume	_
46-18	6527-6532	space	_
46-19	6533-6536	for	_
46-20	6537-6541	each	_
46-21	6542-6549	subject	_
46-22	6550-6551	,	_
46-23	6552-6557	align	_
46-24	6558-6561	the	_
46-25	6562-6568	images	_
46-26	6569-6570	,	_
46-27	6571-6578	perform	_
46-28	6579-6580	a	_
46-29	6581-6583	B1	_
46-30	6584-6594	correction	_
46-31	6595-6596	,	_
46-32	6597-6600	and	_
46-33	6601-6609	register	_
46-34	6610-6613	the	_
46-35	6614-6621	subject	_
46-36	6622-6623	’	_
46-37	6624-6625	s	_
46-38	6626-6636	structural	_
46-39	6637-6643	volume	_
46-40	6644-6649	space	_
46-41	6650-6652	to	_
46-42	6653-6656	the	_
46-43	6657-6660	MNI	_
46-44	6661-6666	space	_
46-45	6667-6668	.	_

47-1	6669-6672	The	_
47-2	6673-6679	second	_
47-3	6680-6684	part	_
47-4	6685-6687	of	_
47-5	6688-6691	the	_
47-6	6692-6700	pipeline	_
47-7	6701-6703	is	_
47-8	6704-6709	based	_
47-9	6710-6712	on	_
47-10	6713-6723	FreeSurfer	_
47-11	6724-6731	version	_
47-12	6732-6735	5.2	_
47-13	6736-6737	(	_
47-14	6738-6742	http	_
47-15	6743-6744	:	_
47-16	6745-6773	//surfer.nmr.mgh.harvard.edu	_
47-17	6774-6775	)	_
47-18	6776-6777	.	_

48-1	6778-6782	This	_
48-2	6783-6791	pipeline	_
48-3	6792-6799	ensures	_
48-4	6800-6804	that	_
48-5	6805-6808	the	_
48-6	6809-6815	volume	_
48-7	6816-6818	is	_
48-8	6819-6828	segmented	_
48-9	6829-6833	into	_
48-10	6834-6844	predefined	_
48-11	6845-6855	structures	_
48-12	6856-6857	,	_
48-13	6858-6862	that	_
48-14	6863-6866	the	_
48-15	6867-6872	white	_
48-16	6873-6876	and	_
48-17	6877-6881	pial	_
48-18	6882-6890	surfaces	_
48-19	6891-6894	are	_
48-20	6895-6908	reconstructed	_
48-21	6909-6910	,	_
48-22	6911-6914	and	_
48-23	6915-6919	that	_
48-24	6920-6930	FreeSurfer	_
48-25	6931-6932	’	_
48-26	6933-6934	s	_
48-27	6935-6942	folding	_
48-28	6943-6948	based	_
48-29	6949-6956	surface	_
48-30	6957-6969	registration	_
48-31	6970-6971	(	_
48-32	6972-6974	to	_
48-33	6975-6978	the	_
48-34	6979-6986	surface	_
48-35	6987-6992	atlas	_
48-36	6993-7002	fsaverage	_
48-37	7003-7004	)	_
48-38	7005-7007	is	_
48-39	7008-7017	performed	_
48-40	7018-7019	.	_

49-1	7020-7030	Structural	_
49-2	7031-7035	data	_
49-3	7036-7044	analyzed	_
49-4	7045-7048	for	_
49-5	7049-7052	the	_
49-6	7053-7060	current	_
49-7	7061-7066	study	_
49-8	7067-7071	came	_
49-9	7072-7076	from	_
49-10	7077-7081	this	_
49-11	7082-7088	second	_
49-12	7089-7093	step	_
49-13	7094-7095	.	_

50-1	7096-7100	This	_
50-2	7101-7109	pipeline	_
50-3	7110-7119	generates	_
50-4	7120-7122	34	_
50-5	7123-7133	anatomical	_
50-6	7134-7141	regions	_
50-7	7142-7144	of	_
50-8	7145-7153	interest	_
50-9	7154-7155	(	_
50-10	7156-7160	ROIs	_
50-11	7161-7162	)	_
50-12	7163-7166	per	_
50-13	7167-7175	cortical	_
50-14	7176-7186	hemisphere	_
50-15	7187-7188	.	_

51-1	7189-7192	The	_
51-2	7193-7197	mean	_
51-3	7198-7206	cortical	_
51-4	7207-7216	thickness	_
51-5	7217-7219	in	_
51-6	7220-7224	each	_
51-7	7225-7227	of	_
51-8	7228-7231	the	_
51-9	7232-7234	68	_
51-10	7235-7239	ROIs	_
51-11	7240-7243	was	_
51-12	7244-7252	provided	_
51-13	7253-7256	per	_
51-14	7257-7263	person	_
51-15	7264-7266	in	_
51-16	7267-7270	the	_
51-17	7271-7274	HCP	_
51-18	7275-7281	public	_
51-19	7282-7289	dataset	_
51-20	7290-7291	.	_

52-1	7292-7301	Selection	_
52-2	7302-7304	of	_
52-3	7305-7312	Regions	_
52-4	7313-7315	of	_
52-5	7316-7324	Interest	_
52-6	7325-7327	We	_
52-7	7328-7336	examined	_
52-8	7337-7345	cortical	_
52-9	7346-7355	thickness	_
52-10	7356-7358	in	_
52-11	7359-7360	a	_
52-12	7361-7367	series	_
52-13	7368-7370	of	_
52-14	7371-7372	a	_
52-15	7373-7379	priori	_
52-16	7380-7387	regions	_
52-17	7388-7392	that	_
52-18	7393-7397	were	_
52-19	7398-7404	chosen	_
52-20	7405-7410	based	_
52-21	7411-7413	on	_
52-22	7414-7422	previous	_
52-23	7423-7430	studies	_
52-24	7431-7433	on	_
52-25	7434-7442	cortical	_
52-26	7443-7452	thickness	_
52-27	7453-7455	in	_
52-28	7456-7463	alcohol	_
52-29	7464-7467	use	_
52-30	7468-7475	samples	_
52-31	7476-7477	.	_

53-1	7478-7490	Specifically	_
53-2	7491-7492	,	_
53-3	7493-7495	we	_
53-4	7496-7506	identified	_
53-5	7507-7509	18	_
53-6	7510-7519	bilateral	_
53-7	7520-7524	ROIs	_
53-8	7525-7529	that	_
53-9	7530-7534	have	_
53-10	7535-7540	shown	_
53-11	7541-7552	significant	_
53-12	7553-7564	differences	_
53-13	7565-7567	in	_
53-14	7568-7570	at	_
53-15	7571-7576	least	_
53-16	7577-7580	one	_
53-17	7581-7583	of	_
53-18	7584-7589	these	_
53-19	7590-7595	prior	_
53-20	7596-7603	studies	_
53-21	7604-7605	.	_

54-1	7606-7615	Following	_
54-2	7616-7627	conventions	_
54-3	7628-7632	used	_
54-4	7633-7635	in	_
54-5	7636-7641	prior	_
54-6	7642-7649	studies	_
54-7	7650-7651	(	_
54-8	7652-7656	e.g.	_
54-9	7657-7658	,	_
54-10	7659-7660	)	_
54-11	7661-7662	,	_
54-12	7663-7664	a	_
54-13	7665-7671	subset	_
54-14	7672-7674	of	_
54-15	7675-7680	these	_
54-16	7681-7688	regions	_
54-17	7689-7693	were	_
54-18	7694-7702	combined	_
54-19	7703-7707	into	_
54-20	7708-7717	composite	_
54-21	7718-7725	regions	_
54-22	7726-7739	corresponding	_
54-23	7740-7742	to	_
54-24	7743-7746	the	_
54-25	7747-7750	ACC	_
54-26	7751-7752	,	_
54-27	7753-7756	OFC	_
54-28	7757-7758	,	_
54-29	7759-7762	IFG	_
54-30	7763-7764	,	_
54-31	7765-7768	and	_
54-32	7769-7774	DLPFC	_
54-33	7775-7776	,	_
54-34	7777-7785	reducing	_
54-35	7786-7789	the	_
54-36	7790-7796	number	_
54-37	7797-7799	of	_
54-38	7800-7807	regions	_
54-39	7808-7812	from	_
54-40	7813-7815	18	_
54-41	7816-7818	to	_
54-42	7819-7821	12	_
54-43	7822-7823	.	_

55-1	7824-7827	The	_
55-2	7828-7831	ACC	_
55-3	7832-7841	composite	_
55-4	7842-7848	region	_
55-5	7849-7852	was	_
55-6	7853-7860	created	_
55-7	7861-7863	by	_
55-8	7864-7873	combining	_
55-9	7874-7877	the	_
55-10	7878-7884	caudal	_
55-11	7885-7888	and	_
55-12	7889-7896	rostral	_
55-13	7897-7900	ACC	_
55-14	7901-7909	segments	_
55-15	7910-7911	.	_

56-1	7912-7915	The	_
56-2	7916-7921	DLPFC	_
56-3	7922-7931	composite	_
56-4	7932-7935	was	_
56-5	7936-7943	created	_
56-6	7944-7946	by	_
56-7	7947-7956	combining	_
56-8	7957-7960	the	_
56-9	7961-7967	caudal	_
56-10	7968-7971	MFG	_
56-11	7972-7973	,	_
56-12	7974-7981	rostral	_
56-13	7982-7985	MFG	_
56-14	7986-7987	,	_
56-15	7988-7991	and	_
56-16	7992-7995	the	_
56-17	7996-7999	SFG	_
56-18	8000-8008	segments	_
56-19	8009-8010	.	_

57-1	8011-8017	Lastly	_
57-2	8018-8019	,	_
57-3	8020-8023	the	_
57-4	8024-8027	OFC	_
57-5	8028-8037	composite	_
57-6	8038-8041	was	_
57-7	8042-8049	created	_
57-8	8050-8052	by	_
57-9	8053-8062	combining	_
57-10	8063-8066	the	_
57-11	8067-8074	lateral	_
57-12	8075-8078	and	_
57-13	8079-8085	medial	_
57-14	8086-8089	OFC	_
57-15	8090-8098	segments	_
57-16	8099-8100	.	_

58-1	8101-8104	The	_
58-2	8105-8109	only	_
58-3	8110-8118	previous	_
58-4	8119-8124	study	_
58-5	8125-8127	to	_
58-6	8128-8135	observe	_
58-7	8136-8147	significant	_
58-8	8148-8155	results	_
58-9	8156-8159	for	_
58-10	8160-8163	the	_
58-11	8164-8167	IFG	_
58-12	8168-8171	did	_
58-13	8172-8175	not	_
58-14	8176-8184	indicate	_
58-15	8185-8186	a	_
58-16	8187-8195	specific	_
58-17	8196-8209	sub-component	_
58-18	8210-8212	of	_
58-19	8213-8216	the	_
58-20	8217-8220	IFG	_
58-21	8221-8222	(	_
58-22	8223-8227	pars	_
58-23	8228-8239	opercularis	_
58-24	8240-8241	,	_
58-25	8242-8246	pars	_
58-26	8247-8256	orbitalis	_
58-27	8257-8258	,	_
58-28	8259-8263	pars	_
58-29	8264-8276	triangularis	_
58-30	8277-8278	)	_
58-31	8279-8280	,	_
58-32	8281-8283	so	_
58-33	8284-8289	these	_
58-34	8290-8295	three	_
58-35	8296-8303	regions	_
58-36	8304-8308	were	_
58-37	8309-8317	combined	_
58-38	8318-8322	into	_
58-39	8323-8324	a	_
58-40	8325-8331	single	_
58-41	8332-8335	IFG	_
58-42	8336-8345	composite	_
58-43	8346-8352	region	_
58-44	8353-8354	.	_

59-1	8355-8358	The	_
59-2	8359-8364	final	_
59-3	8365-8369	list	_
59-4	8370-8372	of	_
59-5	8373-8375	12	_
59-6	8376-8377	a	_
59-7	8378-8384	priori	_
59-8	8385-8389	ROIs	_
59-9	8390-8393	and	_
59-10	8394-8397	the	_
59-11	8398-8405	studies	_
59-12	8406-8415	reporting	_
59-13	8416-8427	differences	_
59-14	8428-8430	in	_
59-15	8431-8436	these	_
59-16	8437-8442	areas	_
59-17	8443-8445	is	_
59-18	8446-8454	provided	_
59-19	8455-8457	in	_
59-20	8458-8463	Table	_
59-21	8464-8465	1	_
59-22	8466-8467	.	_

60-1	8468-8471	The	_
60-2	8472-8482	anatomical	_
60-3	8483-8492	locations	_
60-4	8493-8495	of	_
60-5	8496-8506	individual	_
60-6	8507-8511	ROIs	_
60-7	8512-8515	and	_
60-8	8516-8525	composite	_
60-9	8526-8533	regions	_
60-10	8534-8537	are	_
60-11	8538-8546	depicted	_
60-12	8547-8549	in	_
60-13	8550-8556	Figure	_
60-14	8557-8558	1	_
60-15	8559-8560	.	_

61-1	8561-8566	These	_
61-2	8567-8571	ROIs	_
61-3	8572-8576	were	_
61-4	8577-8585	examined	_
61-5	8586-8596	separately	_
61-6	8597-8600	for	_
61-7	8601-8604	the	_
61-8	8605-8609	left	_
61-9	8610-8613	and	_
61-10	8614-8619	right	_
61-11	8620-8631	hemispheres	_
61-12	8632-8637	using	_
61-13	8638-8641	the	_
61-14	8642-8649	average	_
61-15	8650-8658	cortical	_
61-16	8659-8668	thickness	_
61-17	8669-8675	values	_
61-18	8676-8679	for	_
61-19	8680-8684	each	_
61-20	8685-8691	region	_
61-21	8692-8700	provided	_
61-22	8701-8703	in	_
61-23	8704-8707	the	_
61-24	8708-8711	HCP	_
61-25	8712-8719	dataset	_
61-26	8720-8721	.	_

62-1	8722-8726	Data	_
62-2	8727-8735	Analytic	_
62-3	8736-8740	Plan	_
62-4	8741-8750	Selection	_
62-5	8751-8753	of	_
62-6	8754-8757	the	_
62-7	8758-8768	covariates	_
62-8	8769-8772	was	_
62-9	8773-8778	based	_
62-10	8779-8781	on	_
62-11	8782-8790	previous	_
62-12	8791-8795	work	_
62-13	8796-8800	that	_
62-14	8801-8804	has	_
62-15	8805-8810	shown	_
62-16	8811-8815	that	_
62-17	8816-8819	age	_
62-18	8820-8821	(	_
62-19	8822-8826	e.g.	_
62-20	8827-8828	,	_
62-21	8829-8830	)	_
62-22	8831-8832	,	_
62-23	8833-8836	sex	_
62-24	8837-8838	(	_
62-25	8839-8843	e.g.	_
62-26	8844-8845	,	_
62-27	8846-8847	)	_
62-28	8848-8849	,	_
62-29	8850-8863	socioeconomic	_
62-30	8864-8870	status	_
62-31	8871-8872	(	_
62-32	8873-8877	e.g.	_
62-33	8878-8879	,	_
62-34	8880-8881	)	_
62-35	8882-8883	,	_
62-36	8884-8893	education	_
62-37	8894-8895	(	_
62-38	8896-8900	e.g.	_
62-39	8901-8902	,	_
62-40	8903-8904	)	_
62-41	8905-8906	,	_
62-42	8907-8910	use	_
62-43	8911-8913	of	_
62-44	8914-8921	tobacco	_
62-45	8922-8923	(	_
62-46	8924-8928	e.g.	_
62-47	8929-8930	,	_
62-48	8931-8932	)	_
62-49	8933-8936	and	_
62-50	8937-8945	cannabis	_
62-51	8946-8949	and	_
62-52	8950-8955	other	_
62-53	8956-8960	drug	_
62-54	8961-8964	use	_
62-55	8965-8966	(	_
62-56	8967-8971	e.g.	_
62-57	8972-8973	,	_
62-58	8974-8975	)	_
62-59	8976-8979	are	_
62-60	8980-8993	significantly	_
62-61	8994-9004	associated	_
62-62	9005-9009	with	_
62-63	9010-9019	variation	_
62-64	9020-9022	in	_
62-65	9023-9031	cortical	_
62-66	9032-9041	thickness	_
62-67	9042-9043	.	_

63-1	9044-9048	Twin	_
63-2	9049-9055	status	_
63-3	9056-9057	(	_
63-4	9058-9062	i.e.	_
63-5	9063-9064	,	_
63-6	9065-9076	monozygotic	_
63-7	9077-9079	or	_
63-8	9080-9083	not	_
63-9	9084-9085	;	_
63-10	9086-9095	dizygotic	_
63-11	9096-9098	or	_
63-12	9099-9102	not	_
63-13	9103-9104	)	_
63-14	9105-9108	was	_
63-15	9109-9117	included	_
63-16	9118-9123	given	_
63-17	9124-9127	the	_
63-18	9128-9132	twin	_
63-19	9133-9143	enrichment	_
63-20	9144-9146	of	_
63-21	9147-9150	the	_
63-22	9151-9154	HCP	_
63-23	9155-9162	dataset	_
63-24	9163-9164	.	_

64-1	9165-9174	Estimated	_
64-2	9175-9180	total	_
64-3	9181-9193	intracranial	_
64-4	9194-9200	volume	_
64-5	9201-9204	was	_
64-6	9205-9213	included	_
64-7	9214-9216	to	_
64-8	9217-9224	control	_
64-9	9225-9228	for	_
64-10	9229-9240	differences	_
64-11	9241-9243	in	_
64-12	9244-9251	overall	_
64-13	9252-9256	head	_
64-14	9257-9261	size	_
64-15	9262-9263	.	_

65-1	9264-9276	Hierarchical	_
65-2	9277-9285	multiple	_
65-3	9286-9292	linear	_
65-4	9293-9303	regression	_
65-5	9304-9310	models	_
65-6	9311-9315	were	_
65-7	9316-9325	conducted	_
65-8	9326-9328	to	_
65-9	9329-9336	examine	_
65-10	9337-9349	associations	_
65-11	9350-9357	between	_
65-12	9358-9366	cortical	_
65-13	9367-9376	thickness	_
65-14	9377-9384	indices	_
65-15	9385-9388	and	_
65-16	9389-9396	alcohol	_
65-17	9397-9406	variables	_
65-18	9407-9408	.	_

66-1	9409-9417	Separate	_
66-2	9418-9428	regression	_
66-3	9429-9435	models	_
66-4	9436-9440	were	_
66-5	9441-9451	calculated	_
66-6	9452-9455	for	_
66-7	9456-9460	each	_
66-8	9461-9463	of	_
66-9	9464-9467	the	_
66-10	9468-9472	ROIs	_
66-11	9473-9474	.	_

67-1	9475-9479	Step	_
67-2	9480-9483	one	_
67-3	9484-9486	of	_
67-4	9487-9490	the	_
67-5	9491-9497	models	_
67-6	9498-9506	included	_
67-7	9507-9510	age	_
67-8	9511-9512	,	_
67-9	9513-9516	sex	_
67-10	9517-9518	,	_
67-11	9519-9528	education	_
67-12	9529-9530	,	_
67-13	9531-9537	income	_
67-14	9538-9539	,	_
67-15	9540-9544	twin	_
67-16	9545-9551	status	_
67-17	9552-9553	,	_
67-18	9554-9559	total	_
67-19	9560-9572	intracranial	_
67-20	9573-9579	volume	_
67-21	9580-9581	,	_
67-22	9582-9589	tobacco	_
67-23	9590-9593	use	_
67-24	9594-9595	,	_
67-25	9596-9604	cannabis	_
67-26	9605-9608	use	_
67-27	9609-9610	,	_
67-28	9611-9614	and	_
67-29	9615-9620	other	_
67-30	9621-9625	drug	_
67-31	9626-9629	use	_
67-32	9630-9632	as	_
67-33	9633-9643	covariates	_
67-34	9644-9645	.	_

68-1	9646-9648	On	_
68-2	9649-9652	the	_
68-3	9653-9658	SSAGA	_
68-4	9659-9660	,	_
68-5	9661-9668	tobacco	_
68-6	9669-9672	use	_
68-7	9673-9676	was	_
68-8	9677-9684	defined	_
68-9	9685-9687	as	_
68-10	9688-9693	total	_
68-11	9694-9701	tobacco	_
68-12	9702-9705	use	_
68-13	9706-9708	in	_
68-14	9709-9712	the	_
68-15	9713-9717	past	_
68-16	9718-9719	7	_
68-17	9720-9724	days	_
68-18	9725-9726	,	_
68-19	9727-9735	cannabis	_
68-20	9736-9739	use	_
68-21	9740-9743	was	_
68-22	9744-9751	defined	_
68-23	9752-9754	as	_
68-24	9755-9758	the	_
68-25	9759-9764	total	_
68-26	9765-9770	times	_
68-27	9771-9783	participants	_
68-28	9784-9792	reported	_
68-29	9793-9798	using	_
68-30	9799-9808	marijuana	_
68-31	9809-9811	on	_
68-32	9812-9815	the	_
68-33	9816-9821	SSAGA	_
68-34	9822-9823	;	_
68-35	9824-9827	and	_
68-36	9828-9833	other	_
68-37	9834-9841	illicit	_
68-38	9842-9846	drug	_
68-39	9847-9850	use	_
68-40	9851-9854	was	_
68-41	9855-9862	defined	_
68-42	9863-9865	as	_
68-43	9866-9869	the	_
68-44	9870-9875	total	_
68-45	9876-9881	times	_
68-46	9882-9894	participants	_
68-47	9895-9904	reporting	_
68-48	9905-9912	cocaine	_
68-49	9913-9914	,	_
68-50	9915-9928	hallucinogens	_
68-51	9929-9930	,	_
68-52	9931-9938	opiates	_
68-53	9939-9940	,	_
68-54	9941-9950	sedatives	_
68-55	9951-9953	or	_
68-56	9954-9959	other	_
68-57	9960-9965	drugs	_
68-58	9966-9968	on	_
68-59	9969-9972	the	_
68-60	9973-9978	SSAGA	_
68-61	9979-9980	.	_

69-1	9981-9983	In	_
69-2	9984-9992	addition	_
69-3	9993-9995	to	_
69-4	9996-9999	the	_
69-5	10000-10010	selfreport	_
69-6	10011-10015	drug	_
69-7	10016-10019	use	_
69-8	10020-10029	variables	_
69-9	10030-10031	,	_
69-10	10032-10033	a	_
69-11	10034-10040	binary	_
69-12	10041-10049	variable	_
69-13	10050-10053	was	_
69-14	10054-10064	calculated	_
69-15	10065-10070	based	_
69-16	10071-10073	on	_
69-17	10074-10077	any	_
69-18	10078-10086	positive	_
69-19	10087-10093	screen	_
69-20	10094-10096	on	_
69-21	10097-10100	the	_
69-22	10101-10106	urine	_
69-23	10107-10111	drug	_
69-24	10112-10116	test	_
69-25	10117-10118	(	_
69-26	10119-10120	1	_
69-27	10121-10122	=	_
69-28	10123-10126	any	_
69-29	10127-10135	positive	_
69-30	10136-10137	;	_
69-31	10138-10139	0	_
69-32	10140-10141	=	_
69-33	10142-10145	all	_
69-34	10146-10154	negative	_
69-35	10155-10156	)	_
69-36	10157-10158	.	_

70-1	10159-10163	Each	_
70-2	10164-10172	cortical	_
70-3	10173-10182	thickness	_
70-4	10183-10186	ROI	_
70-5	10187-10190	was	_
70-6	10191-10196	added	_
70-7	10197-10199	in	_
70-8	10200-10203	the	_
70-9	10204-10210	second	_
70-10	10211-10215	step	_
70-11	10216-10218	of	_
70-12	10219-10222	the	_
70-13	10223-10228	model	_
70-14	10229-10232	and	_
70-15	10233-10239	change	_
70-16	10240-10242	in	_
70-17	10243-10245	R2	_
70-18	10246-10249	was	_
70-19	10250-10258	examined	_
70-20	10259-10260	.	_

71-1	10261-10269	Separate	_
71-2	10270-10280	regression	_
71-3	10281-10287	models	_
71-4	10288-10292	were	_
71-5	10293-10303	calculated	_
71-6	10304-10307	for	_
71-7	10308-10314	drinks	_
71-8	10315-10317	in	_
71-9	10318-10322	past	_
71-10	10323-10327	week	_
71-11	10328-10331	and	_
71-12	10332-10341	frequency	_
71-13	10342-10344	of	_
71-14	10345-10350	heavy	_
71-15	10351-10359	drinking	_
71-16	10360-10361	.	_

72-1	10362-10367	Given	_
72-2	10368-10371	the	_
72-3	10372-10382	relatively	_
72-4	10383-10388	large	_
72-5	10389-10395	number	_
72-6	10396-10398	of	_
72-7	10399-10403	ROIs	_
72-8	10404-10405	,	_
72-9	10406-10408	we	_
72-10	10409-10416	applied	_
72-11	10417-10418	a	_
72-12	10419-10429	two-tailed	_
72-13	10430-10435	False	_
72-14	10436-10445	Discovery	_
72-15	10446-10450	Rate	_
72-16	10451-10452	(	_
72-17	10453-10456	FDR	_
72-18	10457-10458	)	_
72-19	10459-10469	correction	_
72-20	10470-10472	of	_
72-21	10473-10474	q	_
72-22	10475-10476	<	_
72-23	10477-10480	.05	_
72-24	10481-10483	to	_
72-25	10484-10490	reduce	_
72-26	10491-10500	inflation	_
72-27	10501-10503	of	_
72-28	10504-10508	type	_
72-29	10509-10510	I	_
72-30	10511-10516	error	_
72-31	10517-10521	rate	_
72-32	10522-10524	in	_
72-33	10525-10528	the	_
72-34	10529-10539	individual	_
72-35	10540-10550	regression	_
72-36	10551-10559	analyses	_
72-37	10560-10561	.	_

73-1	10562-10564	We	_
73-2	10565-10569	then	_
73-3	10570-10579	conducted	_
73-4	10580-10582	an	_
73-5	10583-10592	iterative	_
73-6	10593-10603	regression	_
73-7	10604-10612	analysis	_
73-8	10613-10615	to	_
73-9	10616-10625	determine	_
73-10	10626-10629	the	_
73-11	10630-10636	unique	_
73-12	10637-10650	contributions	_
73-13	10651-10653	of	_
73-14	10654-10657	the	_
73-15	10658-10662	ROIs	_
73-16	10663-10667	that	_
73-17	10668-10672	were	_
73-18	10673-10686	significantly	_
73-19	10687-10697	associated	_
73-20	10698-10702	with	_
73-21	10703-10706	the	_
73-22	10707-10715	drinking	_
73-23	10716-10725	variables	_
73-24	10726-10728	in	_
73-25	10729-10732	the	_
73-26	10733-10743	individual	_
73-27	10744-10754	regression	_
73-28	10755-10761	models	_
73-29	10762-10763	,	_
73-30	10764-10769	after	_
73-31	10770-10780	correcting	_
73-32	10781-10784	for	_
73-33	10785-10793	multiple	_
73-34	10794-10805	comparisons	_
73-35	10806-10807	(	_
73-36	10808-10815	similar	_
73-37	10816-10818	to	_
73-38	10819-10822	the	_
73-39	10823-10831	approach	_
73-40	10832-10836	used	_
73-41	10837-10839	in	_
73-42	10840-10841	.	_

74-1	10842-10844	In	_
74-2	10845-10850	these	_
74-3	10851-10857	models	_
74-4	10858-10859	,	_
74-5	10860-10870	individual	_
74-6	10871-10875	ROIs	_
74-7	10876-10880	that	_
74-8	10881-10885	were	_
74-9	10886-10891	found	_
74-10	10892-10894	to	_
74-11	10895-10897	be	_
74-12	10898-10908	associated	_
74-13	10909-10913	with	_
74-14	10914-10921	alcohol	_
74-15	10922-10925	use	_
74-16	10926-10928	at	_
74-17	10929-10932	FDR	_
74-18	10933-10934	q	_
74-19	10935-10936	<	_
74-20	10937-10940	.05	_
74-21	10941-10943	in	_
74-22	10944-10947	the	_
74-23	10948-10956	previous	_
74-24	10957-10961	step	_
74-25	10962-10966	were	_
74-26	10967-10974	entered	_
74-27	10975-10987	sequentially	_
74-28	10988-10996	starting	_
74-29	10997-11001	with	_
74-30	11002-11005	the	_
74-31	11006-11013	largest	_
74-32	11014-11020	effect	_
74-33	11021-11025	size	_
74-34	11026-11029	and	_
74-35	11030-11040	proceeding	_
74-36	11041-11043	to	_
74-37	11044-11047	the	_
74-38	11048-11056	smallest	_
74-39	11057-11063	effect	_
74-40	11064-11068	size	_
74-41	11069-11070	.	_

75-1	11071-11073	At	_
75-2	11074-11078	each	_
75-3	11079-11088	iteration	_
75-4	11089-11090	,	_
75-5	11091-11095	ROIs	_
75-6	11096-11100	that	_
75-7	11101-11114	significantly	_
75-8	11115-11124	increased	_
75-9	11125-11128	the	_
75-10	11129-11137	variance	_
75-11	11138-11147	explained	_
75-12	11148-11150	by	_
75-13	11151-11154	the	_
75-14	11155-11160	model	_
75-15	11161-11162	(	_
75-16	11163-11167	i.e.	_
75-17	11168-11169	,	_
75-18	11170-11173	had	_
75-19	11174-11175	a	_
75-20	11176-11187	significant	_
75-21	11188-11191	ΔR2	_
75-22	11192-11193	)	_
75-23	11194-11198	were	_
75-24	11199-11207	retained	_
75-25	11208-11210	in	_
75-26	11211-11214	the	_
75-27	11215-11220	model	_
75-28	11221-11222	.	_

76-1	11223-11226	The	_
76-2	11227-11236	iterative	_
76-3	11237-11247	regression	_
76-4	11248-11256	analysis	_
76-5	11257-11261	used	_
76-6	11262-11263	a	_
76-7	11264-11276	conventional	_
76-8	11277-11289	significance	_
76-9	11290-11295	level	_
76-10	11296-11298	of	_
76-11	11299-11300	p	_
76-12	11301-11302	<	_
76-13	11303-11306	.05	_
76-14	11307-11310	and	_
76-15	11311-11313	95	_
76-16	11314-11315	%	_
76-17	11316-11326	confidence	_
76-18	11327-11336	intervals	_
76-19	11337-11340	are	_
76-20	11341-11349	reported	_
76-21	11350-11353	for	_
76-22	11354-11364	regression	_
76-23	11365-11377	coefficients	_
76-24	11378-11379	.	_

77-1	11380-11387	Finally	_
77-2	11388-11389	,	_
77-3	11390-11392	we	_
77-4	11393-11402	conducted	_
77-5	11403-11406	two	_
77-6	11407-11418	exploratory	_
77-7	11419-11427	analyses	_
77-8	11428-11429	.	_

78-1	11430-11435	First	_
78-2	11436-11437	,	_
78-3	11438-11440	we	_
78-4	11441-11449	examined	_
78-5	11450-11459	potential	_
78-6	11460-11463	sex	_
78-7	11464-11474	difference	_
78-8	11475-11487	associations	_
78-9	11488-11495	between	_
78-10	11496-11504	cortical	_
78-11	11505-11514	thickness	_
78-12	11515-11518	and	_
78-13	11519-11522	the	_
78-14	11523-11530	alcohol	_
78-15	11531-11540	variables	_
78-16	11541-11543	by	_
78-17	11544-11553	repeating	_
78-18	11554-11557	the	_
78-19	11558-11565	primary	_
78-20	11566-11574	analyses	_
78-21	11575-11576	(	_
78-22	11577-11581	i.e.	_
78-23	11582-11583	,	_
78-24	11584-11587	the	_
78-25	11588-11600	hierarchical	_
78-26	11601-11609	multiple	_
78-27	11610-11616	linear	_
78-28	11617-11627	regression	_
78-29	11628-11634	models	_
78-30	11635-11636	)	_
78-31	11637-11646	including	_
78-32	11647-11649	an	_
78-33	11650-11661	interaction	_
78-34	11662-11666	term	_
78-35	11667-11671	that	_
78-36	11672-11675	was	_
78-37	11676-11686	calculated	_
78-38	11687-11689	by	_
78-39	11690-11703	standardizing	_
78-40	11704-11708	each	_
78-41	11709-11715	region	_
78-42	11716-11719	and	_
78-43	11720-11723	sex	_
78-44	11724-11725	,	_
78-45	11726-11730	then	_
78-46	11731-11742	multiplying	_
78-47	11743-11747	each	_
78-48	11748-11754	region	_
78-49	11755-11757	by	_
78-50	11758-11761	sex	_
78-51	11762-11763	.	_

79-1	11764-11767	All	_
79-2	11768-11770	24	_
79-3	11771-11775	ROIs	_
79-4	11776-11780	were	_
79-5	11781-11789	examined	_
79-6	11790-11793	and	_
79-7	11794-11796	an	_
79-8	11797-11800	FDR	_
79-9	11801-11803	of	_
79-10	11804-11805	q	_
79-11	11806-11807	<	_
79-12	11808-11811	.05	_
79-13	11812-11815	was	_
79-14	11816-11820	used	_
79-15	11821-11822	.	_

80-1	11823-11833	Continuous	_
80-2	11834-11846	associations	_
80-3	11847-11854	between	_
80-4	11855-11863	cortical	_
80-5	11864-11873	thickness	_
80-6	11874-11876	in	_
80-7	11877-11880	the	_
80-8	11881-11883	24	_
80-9	11884-11888	ROIs	_
80-10	11889-11892	and	_
80-11	11893-11902	cognitive	_
80-12	11903-11914	performance	_
80-13	11915-11917	on	_
80-14	11918-11921	the	_
80-15	11922-11929	flanker	_
80-16	11930-11933	and	_
80-17	11934-11938	list	_
80-18	11939-11946	sorting	_
80-19	11947-11952	tasks	_
80-20	11953-11957	were	_
80-21	11958-11966	explored	_
80-22	11967-11972	using	_
80-23	11973-11980	Pearson	_
80-24	11981-11993	correlations	_
80-25	11994-11998	with	_
80-26	11999-12001	an	_
80-27	12002-12005	FDR	_
80-28	12006-12008	of	_
80-29	12009-12010	q	_
80-30	12011-12012	<	_
80-31	12013-12016	.05	_
80-32	12017-12024	applied	_
80-33	12025-12026	.	_

